Watson Pharmaceuticals news from FiercePharma
NewsExpert panel to mull broader Fentora use
Everyone suddenly has an opinion on Fentora. Good opinion: The Cephalon painkiller got European approval a couple of weeks ago, after two years on the market in the U.S. Another good opinion, in the Read more...
ALSO NOTED: Smith & Nephew probes sales infractions; FDA gives nod to expanded Advair use; Eisai wins round in Aricept reimburs
> Smith & Nephew said "unacceptable" sales practices in a business it bought last year will cost it more than $100 million in lost sales and around $25 million in profits; the company has Read more...
ALSO NOTED: FDA lifts ban on Watson plant in FL; Sanofi bolstered profits but lost in drug trial;
> Watson Pharmaceuticals finally saw the FDA lift its ban on new products from a Florida manufacturing plant, allowing drugs made there to be eligible for agency approval; the facility had been Read more...
ALSO NOTED: Bayer sues Watson over Yasmin; Zimmer weeds out doc conflicts
> Open another chapter in the Bayer fight to protect Yasmin patents: Watson Pharmaceuticals filed for FDA approval for its copycat version of the birth control pill, and Bayer sued to keep the Read more...
SPOTLIGHT: Wyeth sues Watson to quash generic
It's Watson Pharmaceuticals and Wyeth in the ring, as Watson filed for FDA approval to sell a generic version of Lybrel, a birth control pill, and Wyeth responded by suing for patent infringement. Read more...
ALSO NOTED: Government could force doc disclosures; Barr sues Watson over Seasonique patent;
> The government is considering requiring pharma companies to disclose their doc-consulting deals as part of any settlement agreements. Read more...
Fosamax leads 2008 patent retreat
Fosamax is dead! Long live generic Fosamax! Reporters took the osteoporosis drug's patent expiration today as an opportunity to remind us all that Read more...
ALSO NOTED: Japan to get Roche's Tarceva next week; Barr sues two generics makers over Seasonale;
> Roche's Japanese unit Chugai Pharmaceutical is preparing to launch the lung-cancer drug Tarceva, approved in Japan in October for treatment of the non-small cell form of the disease. Read more...
In Puerto Rico, costs send pharma packing
Poor Puerto Rico. Pharmaceuticals firms are shutting down plants in the U.S. territory, eliminating some 3,000 jobs. Reasons for the closures include Big Pharma's worldwide restructuring, Puerto Read more...
ALSO NOTED: GSK preps for India drug launches; Watson proceeds with challenge to Bayer drug;
> GlaxoSmithKline is preparing to launch its breast cancer drug Tykerb in India by early next year, with critical care and cardio drugs to follow. Read more...
| Press ReleasesPRESS RELEASE: Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia Fe Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia Fe FAJARDO, Puerto Rico and CORONA, Calif., Oct 29, 2007 -- Warner Chilcott Company, Inc. and Watson Pharmaceuticals, Inc. Read more... |
Get more Watson Pharmaceuticals coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight